South Korea's drug safety agency has approved clinical trials of vaccine and treatment candidates currently under development by two local drug manufacturers, reported The Korea Bizwire.
The Ministry of Food and Drug Safety gave the green light to conduct a Phase I trial of a vaccine candidate NBP 2001 by SK Bioscience.
The company said it will administer the investigative therapy to healthy adults to evaluate its safety and efficacy at two different testing sites.
The drug ministry also approved a Phase II trial using new drug candidate DW2008 by pharmaceutical firm DongWha Pharm to treat COVID-19.
The candidate will be administered to adult COVID-19 patients with severe symptoms to evaluate safety and efficacy, the company said.
In preclinical studies, DW2008 demonstrated that it improves lung function and also had higher antiviral activity compared to remdesivir and Kaletra, according to DongWha Pharm.
To read more NewsPoints articles, click here.